Company:  SEATTLE GENETICS INC /WA (SGEN)
Form Type:  8-K
Filing Date:  11/3/2011 
CIK:  0001060736 
Address:  21823 30TH DRIVE SE
SUITE
 
City, State, Zip:  BOTHELL, Washington 98021 
Telephone:  (425) 527-4000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$39.33  
Change: 
-0.46 (-1.16%)  
Trade Time: 
Apr 24  
Market Cap: 
$4.84B
Description of Business
Seattle Genetics is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer. Our marketed product ADCETRIS�, or brentuximab vedotin, received accelerated approval in the United States in August 2011 and approval with conditions in Canada in February 2013 for patients with relapsed Hodgkin lymphoma or relapsed systemic anaplastic large cell lymphoma, or sALCL. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing our proprietary technology. We have a broad development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy for patients with Hodgkin lymphoma or mature T-cell lymphoma, including sALCL, or MTCL, and in other CD30-positive malignancies.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02 Results of Operations and Financial Condition.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURES
    INDEX TO EXHIBITS
  EXHIBIT 99.1
    BALANCE SHEET
    INCOME STATEMENT
BROKERAGE PARTNERS